Document Detail


Endothelial progenitor cell-based therapy for pulmonary arterial hypertension.
MedLine Citation:
PMID:  23295102     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
A growing body of evidence in animal models and clinical studies supports the concept that endothelial progenitor cell (EPC)-mediated therapy ameliorates pulmonary arterial hypertension (PAH), and thus may represent a novel approach to treat it. Conversely, several experimental findings suggest that EPCs may be involved in PAH pathogenesis and disease progression. These discrepant results confuse the application of EPC transplantation as an effective treatment strategy for PAH. To improve the study of EPC transplantation in PAH therapy, it is high time that we resolved this dilemma. In this review, we examine the pathobiological changes of PAH, the characteristics of EPCs, and the underlying mechanisms of EPC effects on PAH.
Authors:
Jin-Xiu Yang; Yan-Yun Pan; You-Yang Zhao; Xing-Xiang Wang
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-2
Journal Detail:
Title:  Cell transplantation     Volume:  -     ISSN:  1555-3892     ISO Abbreviation:  Cell Transplant     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-8     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9208854     Medline TA:  Cell Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Contrast enhanced transesophageal echocardiography in patients with atrial fibrillation referred to ...
Next Document:  Practical health co-operation - the impact of a referral template on quality of care and health care...